Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

Print Email

Stocks were indicated to open higher on Tuesday in what looks like a broad rally. With the Dow still down about 500 points from the April highs, investors still seem to be looking for opportunities ahead. Buying the dips has not died.

24/7 Wall St. reviews dozens of analyst research reports each morning of the week to find new investing and trading ideas. Some of these analyst reports cover stocks to buy, while other reports cover stocks to sell or avoid.

These are the top analyst upgrades, downgrades and initiations seen on Tuesday morning:

Bats Global Markets Inc. (BATS) saw its post-IPO quiet period come to an end. The stock was started as Neutral with a $28 price objective at Merrill Lynch. Jefferies started it as Hold with a $28 price target. Morgan Stanley started it as Equal Weight.

Eli Lilly & Co. (NYSE: LLY) was added to the prized US 1 list (focus list) at Merrill Lynch. The firm called it a compelling entry point and event path into year-end with solid risk/reward into its breast cancer (abema breast cancer data at ASCO) and Alzheimer’s updates. It has a consensus analyst price target of $95.95 and a 52-week trading range of $67.88 to $92.85.


Gap Inc. (NYSE: GPS) posted disappointing April results with poor margins, and shares were last seen down 12% at $19.15 in early trading. The stock was maintained as Underperform at Credit Suisse, but the target was cut to $21 from $27. Jefferies maintained its Buy rating but cut its target to $28 from $34. Topeka Capital Markets downgraded Gap to Hold from Buy.

Hasbro Inc. (NASDAQ: HAS) was downgraded to Neutral from Overweight at Piper Jaffray. It closed at $86.11, has an $86.33 consensus target price and has a 52-week range of $60.38 to $88.53.

JD.com Inc. (NASDAQ: JD) was downgraded to Neutral from Outperform at Credit Suisse. The firm cut earnings estimates more than 40% based on lower gross merchandise values and margins, dropping its target to $21 from $38 (versus a $23.43 close, after a 7% drop). The consensus price target is $35.29, and the 52-week range is $21.55 to $38.00.

Nike Inc. (NYSE: NKE) was resumed with a Market Perform rating and the valuation range was set at $58 to $62 (versus a $58.72 close) at Wells Fargo. The brand and operations were talked up, but the valuation and competition were cited in the call. The consensus price target is $71.32. The 52-week range is $47.25 to $68.19.

Pfizer Inc. (NYSE: PFE) was removed from the US 1 list (focus list) at Merrill Lynch, after making an adjustment based on the overall composition of the list. Pfizer was maintained as Buy in the call. The consensus price target is $38.48, and the 52-week range is $28.25 to $36.46.

SolarCity Corp. (NASDAQ: SCTY) was maintained as Outperform at Credit Suisse, but the firm cut the price target all the way down to $38 from $62. Merrill Lynch downgraded SolarCity to Neutral from Buy with a $24 price objective. Oppenheimer maintained an Outperform rating but cut its target to $27 from $54. Shares were trading down almost 18% at $18.50 after earnings and guidance, versus a 52-week range of $16.31 to $63.79.

You can follow @Jonogg to get the daily analyst calls and market reports directly on your Twitter feed.

Here are many of the other analyst upgrades, downgrades and initiations seen from Wall Street research calls: